Printer Friendly

ESCAGENETICS' PHYTOPHARMACEUTICALS INC. NAMES SCIENTIFIC ADVISORY BOARD; DR. MEINHART ZENK NAMED CHAIRMAN

 SAN CARLOS, Calif., July 22 /PRNewswire/ -- PHTYOpharmaceuticals Inc. ("PPI"), a subsidiary of ESCAgenetics Corp. (AMEX: ESN), today announced the appointment of three world-renowned scientists, Dr. Meinhart H. Zenk, Dr. John M. Cassady and Dr. William R. "Rod" Sharp to its Scientific Advisory Board. PHYTOpharmaceuticals' business objective is the discovery and development of novel plant-derived pharmaceuticals using a global plant resource network and proprietary plant cell tissue culture technology.
 Zenk, professor and chairman of the Institute of Pharmaceutical Biology, University of Munich, who is a pioneer in the application of plant cell culture to drug discovery, has been named chairman. Cassady is professor of medicinal chemistry and dean of the College of Pharmacy at Ohio State University. Sharp, a co-founder and former vice president of PHYTOpharmaceuticals Inc. and ESCAgenetics Corp., is dean of research of Cook College, Rutgers University and director of research of the university's Agricultural Experiment Station.
 "Drs. Zenk and Cassady are at the leading edge of plant-based drug discovery, and the company is fortunate to benefit from their vast scientific knowledge for the development of the next generation of human therapeutic products," said Dr. Peter Hylands, PHYTOpharmaceuticals Inc.'s vice president of research and chief scientific officer.
 PPI is committed to botanical-based drug discovery. Under Sharp's leadership, PHTYOpharmaceuticals has established collaborations in China, Brazil and Thailand for the collection and production of large numbers of certified plant extracts. "With Professor Zenk, members of the Scientific Advisory Board and the company's in-house scientists, we have put together a first class plant-based drug discovery scientific team," said Dr. Thomas M. Glenn, PHYTOpharmaceuticals' president and chief operating officer.
 ESCAgenetics Corp., PPI's parent company, has successfully produced taxol in plant cell tissue bioreactors and plans to produce taxol in a pilot plant/commercial scale-up facility during 1993, in collaboration with Genencor International Inc. in Rochester, N.Y. In addition, PPI has discovered new taxoids that are related to taxol, as part of its plant cell tissue culture drug discovery program.
 PHYTOpharmaceuticals Inc. is a subsidiary of ESCAgenetics Corp., a publicly traded company that develops and produces high-value, plant- derived products for the pharmaceutical and food processing industries.
 -0- 7/22/93
 /CONTACT: Thomas M. Glenn, president and chief operating officer of PHYTOpharmaceuticals, 415-595-5335; or Raymond J. Moshy, president and chief executive officer of ESCAgenetics, 415-595-5335/
 (ESN)


CO: PHYTOpharmaceuticals Inc.; ESCAgenetics Inc. ST: California IN: MTC SU:

SG-LH -- SF002 -- 4295 07/22/93 08:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 22, 1993
Words:403
Previous Article:SPECIALTY PAPERBOARD REPORTS EARNINGS
Next Article:/THE FOLLOWING IS A REVISION OF A STORY RELEASED EARLIER TODAY/
Topics:


Related Articles
ESCAGENETICS EXPANDS COMMITMENT TO PHYTOPHARMACEUTICALS: APPOINTS VICE PRESIDENT AND COMPLETES PRIVATE FINANCING
ESCAGENETICS NAMES DR. THOMAS M. GLENN PRESIDENT AND CHIEF OPERATING OFFICER OF ITS PHYTOPHARMACEUTICALS SUBSIDIARY
ESCAGENETICS' PHYTOPHARMACEUTICALS INC. NAMES SCIENTIFIC ADVISORY BOARD; DR. MEINHART ZENK NAMED CHAIRMAN
PHYTOPHARMACEUTICALS INC. NAMES DR. MAX WILHELM TO SCIENTIFIC ADVISORY BOARD
PHYTOPHARMACEUTICALS INC. NAMES DR. MAX WILHELM TO SCIENTIFIC ADVISORY BOARD
PHYTOPHARMACEUTICALS INC. NAMES WILLIAM A. HASLER TO BOARD OF DIRECTORS
ESCAGENETICS ELECTS RICHARD E. MOSER PRESIDENT AND CHIEF EXECUTIVE OFFICER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters